All Drugs and Chemicals

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Immunoglobulins, Intravenous

Myeloma Proteins

Paraproteins

Participants will receive AGEN1571 monotherapy.

Participants will receive AGEN1571 with balstilimab.

Participants will receive AGEN1571 with botensilimab.

Participants will receive AGEN1571 with balstilimab and botensilimab.

AGEN1571 administered at the RP2D for monotherapy or any combination therapy.

A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

AGEN1571

A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.

Balstilimab

A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Botensilimab

This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination with balstilimab (PD-1 inhibitor) and/or botensilimab (2-agent combination or 3-agent combination) in participants diagnosed with advanced solid tumors.

Part 1 will be the dose escalation phase to determine the RP2D of AGEN1571 monotherapy or AGEN1571 in combination with balstilimab and/or botensilimab. Part 2 will be the dose expansion phase for specific disease indications. Participants will receive study treatment for up to 2 years, or until any disease progression, unacceptable toxicity, or participant wishes to withdraw consent for any reason.

Study of AGEN1571 in Participants With Advanced Solid Tumors

A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination With a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients With Advanced Solid Tumors

ORR will be determined using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Spots Global Cancer Trial Database for ilt2

Every month we try and update this database with for ilt2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ilt2

Every month we try and update this database with for ilt2 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ilt2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.